Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma

Approximately 50% of melanomas harbor an activating BRAF mutation. Combined BRAF and MEK inhibitors such as dabrafenib and trametinib, vemurafenib and cobimetinib, and encorafenib and binimetinib are US Food and Drug Administration (FDA)-approved to treat patients with BRAF(V600)-mutated advanced me...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Onco Targets Ther
Главные авторы: Kakadia, Sunilkumar, Yarlagadda, Naveen, Awad, Ramez, Kundranda, Madappa, Niu, Jiaxin, Naraev, Boris, Mina, Lida, Dragovich, Tomislav, Gimbel, Mark, Mahmoud, Fade
Формат: Artigo
Язык:Inglês
Опубликовано: Dove Medical Press 2018
Предметы:
Review
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6200076/
https://ncbi.nlm.nih.gov/pubmed/30410366
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S182721
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы